Current Report Filing (8-k)
August 30 2018 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): August 24, 2018
Rennova
Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
001-35141
|
68-0370244
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
400
S. Australian Avenue, Suite 800, West Palm Beach, Florida
|
33401
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company[ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
3.03. Material Modification to Rights of Security Holders.
On
August 24, 2018, Rennova Health, Inc. (the “Company”) filed an Amended Certificate of Designation of Series I-2
Convertible Preferred Stock with the Secretary of State of the State of Delaware to increase the authorized number of shares
of Series I-2 Convertible Preferred Stock (the “Series I-2 Preferred Stock”) that may be issued from
11,271 to 21,346. This amendment was approved by all holders of outstanding shares of the Series I-2 Preferred Stock. As of
August 24, 2018, 421.94233 shares of Series I-2 Preferred Stock have been converted into common stock pursuant to their terms
and there were 3,485.727794 shares of Series I-2 Preferred Stock issued and outstanding.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.
The
information set forth in Item 3.03 is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
August 30, 2018
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
|
Seamus
Lagan
|
|
|
|
Chief
Executive Officer
|
|
|
|
(principal
executive officer)
|